Adagene Inc. — FY2022 Form 20-F
Reporting period: Year ended December 31, 2022. This is an annual report; the filing does not provide a clear standalone Q4 2022 financial breakdown. Amounts below are in U.S. dollars unless stated otherwise.
Business context
Adagene is a clinical-stage biotechnology company developing antibody-based cancer immunotherapies using its DPL, NEObody, SAFEbody and POWERbody platforms. It had no approved products and generated no product-sale revenue; revenue came from licensing and collaboration arrangements. Its principal clinical programs included ADG116 and ADG126 (anti-CTLA-4), ADG106 and ADG206 (anti-CD137), alongside partnered and preclinical programs.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Licensing and collaboration revenue | $9.3 million | $10.2 million |
| Research and development expense | $81.3 million | $68.1 million |
| Administrative expense | $11.9 million | $14.4 million |
| Operating loss | $83.9 million | $72.4 million |
| Net loss | $80.0 million | $73.2 million |
| Net loss per ordinary share, basic and diluted | $1.48 | $1.46 |
| Net cash used in operating activities | $48.6 million | $43.4 million |
| Cash and cash equivalents, year-end | $143.8 million | $174.4 million |
| Total borrowings, year-end | $27.8 million | $7.5 million |
Revenue decreased about 9%; R&D expense increased about 19%, mainly reflecting clinical-program activity and IND-enabling work. Net loss widened about 9%. Cash fell by $30.6 million during 2022. Current assets were $149.3 million against current liabilities of $55.1 million; total liabilities were $69.3 million and shareholders’ equity was $83.1 million. Management said existing cash and cash equivalents were expected to cover anticipated working-capital needs and capital expenditures for at least 12 months, while cautioning that estimates could prove wrong.
FY2022 financing cash flow was $17.8 million, primarily reflecting $25.8 million of borrowing proceeds, offset by $4.4 million of repayments and approximately $4.0 million of share repurchases. Investing cash outflow was $0.7 million. The company reported an accumulated deficit of $258.8 million and expects significant future operating losses. It reported no product sales and no formal earnings or revenue guidance.
Developments, outlook and material risks
- Collaborations: The Sanofi agreement provided a $17.5 million upfront payment in 2022; $9.0 million of revenue was recognized over time. The company also recognized $0.3 million under an ADCT material-transfer and option agreement. Potential milestones and royalties are contingent, not assured revenue.
- Clinical programs: The filing describes ongoing early-stage trials and interim safety and efficacy observations for ADG116, ADG126 and ADG106, plus initiation of a Phase 1 trial for ADG206. These are investigational results, not evidence of approval or established commercial efficacy. The company disclosed a prior FDA clinical hold on ADG116 after a patient death; the hold was lifted in 2019 following protocol changes.
- Funding and execution: Continued development is capital intensive, and additional financing may be needed. Delays, trial failures, safety events, manufacturing constraints, or difficulty enrolling patients could increase costs or impair programs. The company depends on third parties, including a principal clinical-supply manufacturer.
- Related-party and supplier exposure: FY2022 R&D services purchased from WuXi Biologics and WuXi AppTec Group totaled about $35.1 million; $19.3 million was payable to those related parties at year-end. The filing identifies WuXi Biologics as a significant supplier and links the related parties to major shareholders.
- PRC and listing risks: The Cayman Islands holding-company structure, PRC regulatory discretion, cross-border data and human-genetic-resource rules, foreign-exchange controls, and uncertainty around overseas offering filings may affect operations, funding transfers or securities offerings. PCAOB inspection access was restored in 2022, but future access and potential HFCAA trading restrictions remain risks.
- Other notable disclosures: Management concluded internal control over financial reporting was effective at year-end; the filing did not include an auditor attestation. The auditor issued an unqualified opinion on the financial statements and noted adoption of lease accounting in 2022. The company believed it was likely a PFIC for 2022, with significant risk of PFIC status in 2023 and later years. No material legal proceedings were reported.
Most important facts for investors to verify
- Cash runway against the $48.6 million annual operating cash burn, including the effect of borrowing, future trial spending and collaboration receipts.
- Debt terms, maturity schedule and any constraints on cash use or transfers between subsidiaries.
- Whether clinical findings for ADG116, ADG126, ADG106 and ADG206 are confirmed in larger, later-stage studies, and how safety signals affect dosing and development.
- Timing and probability of collaboration milestones, options and royalties; distinguish contingent payments from recognized revenue and cash received.
- Related-party service pricing, supplier concentration, amounts owed and continuity of clinical manufacturing supply.
- Applicability of PRC data, human genetic resources and overseas-listing requirements, and continued PCAOB inspection access.
- Potential dilution from equity awards or future financing, and the U.S. tax consequences if the company is treated as a PFIC.